RedHill Biopharma (RDHL) Stock Overview
A specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
RDHL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
RedHill Biopharma Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.34 |
| 52 Week High | US$6.80 |
| 52 Week Low | US$0.91 |
| Beta | 4.86 |
| 1 Month Change | 11.67% |
| 3 Month Change | -21.18% |
| 1 Year Change | -78.59% |
| 3 Year Change | -99.25% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
This Is Why RedHill Biopharma Ltd.'s (NASDAQ:RDHL) CEO Compensation Looks Appropriate
Sep 10
RedHill Biopharma Ltd. (NASDAQ:RDHL) Might Not Be As Mispriced As It Looks
Jul 28One RedHill Biopharma Ltd. (NASDAQ:RDHL) Analyst Has Been Cutting Their Forecasts
Nov 24RedHill Biopharma receives Nasdaq notification regarding minimum bid price deficiency
Oct 18RedHill wins EU’s orphan drug status to RHB-204 for rare lung disease
Aug 17Shareholder Returns
| RDHL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 30.1% | 1.9% | 1.5% |
| 1Y | -78.6% | 27.8% | 17.3% |
Return vs Industry: RDHL underperformed the US Pharmaceuticals industry which returned 28.1% over the past year.
Return vs Market: RDHL underperformed the US Market which returned 16.7% over the past year.
Price Volatility
| RDHL volatility | |
|---|---|
| RDHL Average Weekly Movement | 14.7% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RDHL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RDHL's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 35 | Dror Ben-Asher | www.redhillbio.com |
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn’s disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults.
RedHill Biopharma Ltd. Fundamentals Summary
| RDHL fundamental statistics | |
|---|---|
| Market cap | US$6.21m |
| Earnings (TTM) | -US$9.31m |
| Revenue (TTM) | US$9.55m |
Is RDHL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RDHL income statement (TTM) | |
|---|---|
| Revenue | US$9.55m |
| Cost of Revenue | US$3.40m |
| Gross Profit | US$6.16m |
| Other Expenses | US$15.47m |
| Earnings | -US$9.31m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.83 |
| Gross Margin | 64.45% |
| Net Profit Margin | -97.52% |
| Debt/Equity Ratio | 0% |
How did RDHL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/08 04:52 |
| End of Day Share Price | 2026/01/08 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
RedHill Biopharma Ltd. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| null null | BTIG |
| Brandon Folkes | Cantor Fitzgerald & Co. |